• All sections
  • C - Chemistrymetallurgy
  • C07D - Heterocyclic compounds
  • C07D 211/36 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Patent holdings for IPC class C07D 211/36

Total number of patents in this class: 67

10-year publication summary

7
5
9
7
1
2
5
3
3
2
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

Principal owners for this class

Owner
All patents
This class
Takeda Pharmaceutical Company Limited
2718
13
Toray Industries, Inc.
7038
3
Eisai R&D Management Co., Ltd.
1183
3
Novo Nordisk A/S
2299
3
The Regents of the University of California
20534
2
ABAC Therapeutics S.L.
7
2
The Broad Institute, Inc.
1927
2
Constellation Pharmaceuticals, Inc.
213
2
Seqirus Inc.
256
2
Bristol-myers Squibb Company
4812
1
F. Hoffmann-La Roche AG
7835
1
AstraZeneca AB
2836
1
AstraZeneca UK Limited
558
1
Bayer AG
3435
1
Massachusetts Institute of Technology
10196
1
The General Hospital Corporation
4809
1
Henkel AG & Co. KGaA
10715
1
Amicus Therapeutics, Inc.
356
1
Amyris, Inc.
365
1
Baruch S. Blumberg Institute
36
1
Other owners 24